Initial Testing (Stage 1) of Temozolomide by the Pediatric Preclinical Testing Program

BACKGROUND: The DNA methylating agent temozolomide was developed primarily for treatment of glioblastoma. However, preclinical data have suggested a broader application for treatment of childhood cancer. Temozolomide was tested against the PPTP solid tumor and ALL models. PROCEDURES: Temozolomide wa...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Pediatr Blood Cancer
Main Authors: Keir, Stephen T., Maris, John M., Reynolds, C. Patrick, Kang, Min H., Kolb, E. Anders, Gorlick, Richard, Lock, Richard, Carol, Hernan, Morton, Christopher L., Wu, Jianrong, Kurmasheva, Raushan T., Houghton, Peter J., Smith, Malcolm A.
Formato: Artigo
Idioma:Inglês
Publicado: 2013
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4244112/
https://ncbi.nlm.nih.gov/pubmed/23335050
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/pbc.24368
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares